Bachrodt Amy 4

What Happened

• Amy Bachrodt, SVP, Finance at Maze Therapeutics, exercised 5,000 stock options on Feb 2, 2026 (4,844 and 156 share tranches) at an exercise price of $10.42/share, paying $52,100 in total. She then sold all 5,000 shares in open-market transactions the same day for aggregate proceeds of $230,219 (sales broken out as 200 shares @ $44.15 = $8,830; 4,064 @ $46.03 = $187,068; 736 @ $46.63 = $34,321). The filing also records the derivative conversion lines related to the option exercise.

Key Details

• Transaction date: Feb 2, 2026; Form 4 filed Feb 4, 2026 (covering the Feb 2 transactions).
• Exercise: 5,000 options at $10.42/share — total cost $52,100.
• Sales: 5,000 shares sold for total proceeds $230,219 (per-line prices noted above); some sales reported as weighted averages with per-share price ranges (see footnotes).
• Shares owned after transaction: not specified in the excerpt of the filing provided here.
• Notable footnotes:
  • F1: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted Sept 29, 2025.
  • F2–F3: Reported sale prices for larger tranches are weighted averages; prices in those tranches ranged across specified per-share ranges (report offers to provide per-price breakdown on request).
  • F4: One option award was fully vested as of Feb 1, 2026.
  • F5: Other awards vest 1/48th monthly beginning Jan 1, 2025 (standard time-based vesting).
• Filing timeliness: transaction reported within standard Form 4 timing (no late filing flag indicated).

Context

• This was an exercise of vested options followed by immediate open-market sales of the resulting shares — effectively an exercise-plus-sale executed under a 10b5-1 plan. Such same-day exercises and sales are common for employees monetizing vested stock awards; the facts here are transactional and do not indicate management’s future view of the company.